?>

Transparency report 2024

28/06/2024

As a member of Polski Związek Pracodawców Przemysłu Farmaceutycznego (PZPPF) and Medi­cine for Europe, Gedeon Richter Polska Sp. z o.o. fully respects the requirements of the Code of Conduct which sets out the rules for disclosing information about cooperation between companies and healthcare professionals/healthcare organisations. This coopera­tion is essential for further development of medicine, and the transparency of these relation­ships is to improve a positive image and cooperation between pharmaceutical companies, healthcare professionals and healthcare organisations.


Other press releases

  • Gedeon Richter and Sumitomo Pharma Receive Positive CHMP Opinion for RYEQO ® for Treatment of Endometriosis
    28/09/2023
  • IQ Medical and Richter announce the sale and purchase of Giskit MD B.V.
    20/07/2023
  • Transparency Report 2022
    11/07/2023
See all press releases

Drugs safety

Patient safety is the most important value for the Gedeon Richter Group. Thus monitoring adverse drug events occurring during pharmacotherapy is especially important for us. We offer to patients and physicians current medical information as well as  we answer all questions regarding the safety of medicinal products.

See all press releases